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study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons
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Methods: Patients with a diagnostic kidney biopsy within 5 years of screening were eligible to join CureGN.
This is a descriptive analysis of clinical and treatment data collected at the time of enrollment.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I gAN and IgAV (also known as Henoch-Schönleinpurpura nephritis) are commonly encountered
glomerular diseases across the age spectrum. IgAN is
the most prevalent primary glomerular disorder in the
world, affecting approximately 2.5 per 100,000 persons
worldwide.1,2 Similarly, IgAV represents 1 of the most
common vasculitides in childhood with a small, but
signiﬁcant, incidence in adults. Although IgAN and
IgAV have common kidney pathology, including the
hallmark ﬁnding of dominant mesangial deposition of
aberrantly glycosylated IgA1, they are different in
presentation and course.3,4 Over the past decade, much
has been learned about the pathogenesis of IgAN, but
progress in the treatment of this disease has been
comparatively stagnant,5–9 and our knowledge about
IgAV as a discrete entity remains limited.4 Similar to
other glomerular diseases, clinical trials have been
sparse and, when present, often have divergentresults.10–14 As a critical step to improve patient
treatments and outcomes, we need to understand the
pathophysiology, genetics, disease trajectories, long-
term outcomes, and biomarkers for patient stratiﬁca-
tion and prognosis.5,15
Recognizing this critical knowledge gap, the Na-
tional Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) funded the CureGN study to estab-
lish a primary glomerular disease consortium with a
focus on IgAN/IgAV, minimal change disease, focal
segmental glomerulosclerosis, and idiopathic membra-
nous nephropathy. Central to the mission of CureGN is
the creation of a longitudinal observational cohort of
adults and children with a biopsy-proven primary
glomerular disease. A unique feature of this cohort is
the use of broad inclusion criteria, seeking to capture
the breadth of disease by all patients from childhood
into adulthood who underwent biopsy within 5 yearsKidney International Reports (2018) 3, 1373–1384
DT Selewski et al.: IgAN and IgAV in Children and Adults CLINICAL RESEARCHof enrollment. The study includes baseline and longi-
tudinal follow-up data, digital pathology images, and
biospecimens. The creation of a digital pathology re-
pository is a key feature of the CureGN cohort that will
allow for standardization of pathology data, grading,
and diagnosis across the 66 institutions. The develop-
ment of such a centralized resource is currently un-
derway; as such, the digital pathology image reporting
and analysis will not be presented here.
In May 2017, 30 months after enrollment
commenced, IgAN/IgAV was the ﬁrst CureGN disease
cohort to reach its recruitment target of 650 patients.
This report represents the initial description of this
cohort. The current study has the following aims: (i) to
describe the baseline characteristics of patients enrolled
in the IgAN/IgAV CureGN cohort; (ii) to compare
clinical characteristics of those with IgAN and IgAV;
(iii) to compare clinical characteristics of adults and
children with IgAN/IgAV; and (iv) to describe treat-
ment patterns in this cohort.
METHODS
Study Sample
CureGN (https://curegn.org/) is a 66-center, NIDDK-
funded, longitudinal, prospective, observational
study. Children (<18 years of age at biopsy) and adults
with a diagnostic biopsy within the past 5 years with
either IgAN or IgAV were eligible for enrollment. Each
enrolling investigator assigned the clinical diagnosis of
IgAV based on the presence of both renal and extra-
renal manifestations (e.g., palpable purpuric rash,
gastrointestinal involvement, arthralgias/arthritis). A
CureGN pathologist validated the pathologic diagnosis
via review of the pathology report and of slides if
indicated. The pathology biopsy criteria included $5
glomeruli available for light microscopic evaluation and
dominant or co-dominant mesangial IgA staining by
immunoﬂuorescence. Electron microscopy was not
required for the diagnosis. Biopsy exclusion criteria
were ﬁndings indicative of another glomerular disease
(IgA-dominant post-infectious glomerulonephritis,
IgA-dominant or co-dominant lupus glomerulone-
phritis and IgA-dominant antiglomerular basement
membrane [GBM] antibody nephritis). Cases of IgAV
lacking renal involvement were not captured in this
cohort.
Exclusion criteria included end-stage kidney disease
or any of the following present prior to the ﬁrst kidney
biopsy: solid organ or bone marrow transplant, active
HIV infection, hepatitis B or C infection, diabetes
mellitus, systemic lupus erythematosus, or active ma-
lignancy. Additional pathology exclusion criteria were
tubulo-interstitial disease, monoclonal gammopathy-Kidney International Reports (2018) 3, 1373–1384related injury, nonparaprotein amyloidosis, granulo-
matous interstitial nephritis, infectious interstitial
nephritis, IgG4-related disease, or sarcoid-related renal
lesions. All enrolled patients provided either informed
consent or assent, as appropriate.
The current report presents enrollment data from
IgAN/IgAV patients in CureGN. The in-person enroll-
ment visit included demographics, disease history,
laboratory data, and clinical characteristics. The latter
comprised duration of disease, family history of kidney
disease, medication history and current use, as well as
comorbidities. Blood and urine samples were also
collected at the enrollment visit and processed centrally
by the CureGN laboratory to measure serum creatinine
and proteinuria in 24-hour, ﬁrst morning void, or spot
urine sample. For adults (aged $18 years), the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
formula and for children the bedside Chronic Kidney
Disease in Children Study or CKiD equation were used
to calculate the eGFR.16,17
Statistical Analyses
Continuous variables are expressed as medians with
interquartile ranges (IQRs), whereas categorical values
are expressed as frequencies and percentages. We
report demographic and clinical data at biopsy and at
enrollment for each diagnosis (IgAN/IgAV), and for
each age group.
We compared demographic, clinical, and medica-
tion data between the 2 disease states overall and by
age. In addition, we compared the pediatric and adult
cohorts separately for the IgAN and IgAV groups.
The MannWhitney U test was used for continuous
variables; a c2 test was used for categorical variables
with at least 5 patients in each group; and the Fisher
exact test was used for categorical variables with
fewer than 5 patients in at least 1 group. Improve-
ment in variables such as eGFR and proteinuria were
deﬁned as absolute change (increase in eGFR and
decrease in proteinuria) between biopsy and enroll-
ment. Multivariable linear models were also used to
assess the effect of age and disease type on eGFR and
log-transformed proteinuria at biopsy and enrollment.
All analyses used SAS software, version 9.4 (SAS
Institute Inc., Cary, NC).
RESULTS
Patient Demographics
A total of 667 patients are enrolled in the CureGN IgA
cohort, including 506 (75.9%) with IgAN and 161
(24.1%) with IgAV. The median disease duration at
enrollment was 1 year (IQR ¼ 0.32.9). Of the patients,
285 (42.7%) were children at the time of biopsy. In all,1375
Table 1. Patient characteristics in the CureGN IgA nephropathy (IgAN)/IgA vasculitis (IgAV) cohort, by diagnosis
All N [ 667 IgAN n [ 506 IgAV n [ 161
P valueaMedian (IQR) or n (%) Median (IQR) or n(%) Median (IQR) or n (%)
Demographicsb
Age at diagnosis, yr 23.9 (12.1–40.9) 28.8 (14.7–43.5) 12.7 (7.6–22.4) <0.001
Age at biopsy, yr 24.3 (12.6–41.8) 29.6 (15.0–43.9) 13.0 (8.3–22.4) <0.001
Time from diagnosis to enrollment, yr 1.0 (0.3–2.9) 1.2 (0.3–3.1) 0.6 (0.2–1.5) <0.001
Sex, male 403 (60.4%) 303 (59.9%) 100 (62.1%) 0.61
Race, white 513 (81.6%) 374 (78.9%) 139 (89.7%) 0.003
Hispanic/Latino 100 (15.1%) 81 (16.1%) 19 (11.8%) 0.18
Family history of kidney disease 188 (29.3%) 149 (30.5%) 39 (25.3%) 0.22
At biopsyc
UPCR 1.5 (0.7–3.3) 1.4 (0.7–3.0) 1.8 (0.7–4.6) 0.04
3 # UPCR 141 (28.5%) 89 (24.9%) 52 (38.0%) 0.01
1 # UPCR < 3 177 (35.8%) 140 (39.2%) 37 (27.0%)
0.3 # UPCR < 1 121 (24.5%) 86 (24.1%) 35 (25.5%)
UPCR < 0.3 55 (11.1%) 42 (11.8%) 13 (9.5%)
Hematuria
Negative 27 (5.5%) 24 (6.8%) 3 (2.2%) 0.03
Trace 17 (3.5%) 15 (4.3%) 2 (1.4%)
1þ Small, 11–25 41 (8.4%) 33 (9.4%) 8 (5.8%)
2þ Moderate, 26–50 105 (21.5%) 78 (22.2%) 27 (19.6%)
3þ Large, 51–250 299 (61.1%) 201 (57.3%) 98 (71.0%)
Serum albumin, g/dl 3.7 (3.2–4.1) 3.8 (3.4–4.1) 3.4 (2.9–3.8) <0.001
Serum albumin <3 g/dl 91 (18.2%) 53 (14.5%) 38 (27.9%) <0.001
eGFR, ml/min per 1.73 m2 78.7 (46.1–110.9) 70.6 (41.8–101.6) 103.5 (70.3–122.5) <0.001
90 # eGFR 239 (41.6%) 150 (35.4%) 89 (59.3%) <0.001
60 # eGFR < 90 131 (22.8%) 97 (22.9%) 34 (22.7%)
30 # eGFR < 60 142 (24.7%) 127 (30.0%) 15 (10.0%)
eGFR <30 62 (10.8%) 50 (11.8%) 12 (8.0%)
At enrollmentd
UPCR 0.6 (0.2–1.7) 0.7 (0.2–1.8) 0.5 (0.2–1.6) 0.37
3 # UPCR 81 (14.9%) 58 (14.4%) 23 (16.2%) 0.33
1 # UPCR < 3 138 (25.3%) 110 (27.3%) 28 (19.7%)
0.3 # UPCR < 1 147 (27.0%) 104 (25.8%) 43 (30.3%)
UPCR <0.3 179 (32.8%) 131 (32.5%) 48 (33.8%)
Hematuria
Negative 84 (16.1%) 68 (17.6%) 16 (11.9%) 0.02
Trace 48 (9.2%) 37 (9.6%) 11 (8.1%)
1þ Small, 11–25 72 (13.8%) 60 (15.5%) 12 (8.9%)
2þ Moderate, 26–50 126 (24.1%) 95 (24.5%) 31 (23.0%)
3þ Large, 51–250 192 (36.8%) 127 (32.8%) 65 (48.1%)
Serum albumin, g/dl 4.0 (3.6–4.3) 4.0 (3.7–4.3) 3.9 (3.4–4.3) 0.03
Serum albumin <3 g/dl 48 (9.7%) 27 (7.3%) 21 (17.1%) 0.001
eGFR, ml/min per 1.73 m2 82.9 (48.8–105.2) 75.8 (43.5–100.1) 100.1 (82.4–118.7) <0.001
90 # eGFR 261 (43.0%) 167 (36.1%) 94 (64.8%) <0.001
60 # eGFR < 90 150 (24.7%) 116 (25.1%) 34 (23.4%)
30 # eGFR < 60 133 (21.9%) 122 (26.4%) 11 (7.6%)
eGFR <30 63 (10.4%) 57 (12.3%) 6 (4.1%)
Hypertensione 121 (19.1%) 89 (18.5%) 32 (20.6%) 0.56
Trajectoryf
eGFR higher at enrollment than at biopsy 215 (40.6%) 156 (39.6%) 59 (43.7%) 0.40
UPCR lower at enrollment than at biopsy 267 (62.8%) 186 (62.0%) 81 (64.8%) 0.59
UPCR ever <0.3 prior to or at enrollment 247 (39.3%) 184 (38.9%) 63 (40.6%) 0.70
eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; UPCR, urine protein-to-creatinine ratio.
aP value from MannWhitney U test for continuous variables, c2 test, or Fisher exact test for categorical variables.
bLess than 6% missing for demographic variables.
cTotal of 26% of UPCR, 27% of hematuria, 25% of serum albumin, and 14% of eGFR values unavailable at biopsy.
dTotal of 18% of UPCR, 22% of hematuria, 26% of serum albumin, 9% of eGFR, and 5% of hypertension values missing at enrollment.
eSystolic blood pressure >140 or diastolic blood pressure >90 for adults; systolic or diastolic blood pressure >95th percentile for pediatric patients.
fTotal of 21% of eGFR trajectories and 36% of UPCR trajectories unavailable (trajectories require nonmissing values at biopsy and enrollment), and 6% of patients had no UPCR
measurements recorded prior to or at enrollment.
CLINICAL RESEARCH DT Selewski et al.: IgAN and IgAV in Children and Adults513 of the cohort (81.6%) self-reported as white and
100 (15.1%) as Hispanic/Latino. At the time of biopsy,
64.3% of the CureGN IgA cohort with a urine protein-
to-creatinine ratio (UPCR) measurement had a UPCR >11376g/g. Demographic characteristics and laboratory values
at biopsy and enrollment are presented in Table 1.
Figure 1 shows the age distribution of the cohort by
disease.Kidney International Reports (2018) 3, 1373–1384
Figure 1. Distribution of patient age at biopsy, by IgA nephropathy
(IgAN) and IgA vasculitis (IgAV).
DT Selewski et al.: IgAN and IgAV in Children and Adults CLINICAL RESEARCHOverall Comparison of IgAN and IgAV
Comparisons between IgAN and IgAV patients are
provided in Table 1. In comparison to patients with
IgAN, those with IgAV were younger at diagnosis
(median 12.7 years [IQR ¼ 7.622.4] vs. 28.8 years
[IQR ¼ 14.743.5], P < 0.001) and were more likely
to be of white race (89.7% vs. 78.9%, P ¼ 0.003). At
the time of biopsy, those with IgAV had higher
UPCR, more hematuria, and lower serum albumin,
but a signiﬁcantly higher median eGFR (103.5 ml/min
per 1.73 m2 [IQR ¼ 70.3122.5] vs. 70.6 ml/min per
1.73 m2 [IQR ¼ 41.8101.6], P < 0.001). At the time
of enrollment, the IgAV cohort continued to show
higher levels of hematuria and lower serum albumin
levels, but no signiﬁcant difference in proteinuria.
From biopsy to enrollment, more IgAV patients had
an increase in their eGFR and decrease in UPCR
compared to IgAN patients (eGFR: 43.7% vs. 39.6%,
UPCR: 64.8% vs. 62.0%); however, this difference
was not statistically signiﬁcant. The disease duration
at enrollment was shorter for IgAV compared to
IgAN.
Comparison of IgAN to IgAV Within Pediatric
and Adult Cohorts
Table 2 presents the demographics and laboratory
data for adult and pediatric patients, comparing
diseases within each age group. Of the 285 pediatric
patients, 112 (39.3%) had IgAV. These 112 patients
were younger, had shorter disease duration, and at
biopsy had a lower serum albumin as well as a higher
degree of proteinuria, compared to the 173 children
with IgAN. These laboratory differences persisted at
enrollment. Although there was a signiﬁcant differ-
ence in eGFR at enrollment, both pediatric cohorts
had a median eGFR >95 ml/min per 1.73 m2 at biopsyKidney International Reports (2018) 3, 1373–1384and enrollment. At the time of biopsy, 50.8% of
pediatric IgAN and 64.4% of pediatric IgAV patients
with an available UPCR measure had UPCR >1 g/g.
There was substantial reduction in proteinuria in
both pediatric IgA cohorts from biopsy to enroll-
ment, resulting in normalization of the UPCR
to <0.3 g/g in 49.7% and 35.9% with IgAN and
IgAV, respectively.
Among the 382 adult patients (333 [87.2%] with
IgAN and 49 [12.8%] with IgAV), demographics were
similar across diseases (Table 2). However, those pa-
tients with IgAV had signiﬁcantly more hematuria
and lower serum albumin at biopsy. The median
eGFR did not differ signiﬁcantly between adults with
IgAN and IgAV at the time of biopsy (51.8 ml/min per
1.73m2 [IQR ¼ 36.087.2] vs. 67.3 ml/min per 1.73 m2
[IQR ¼ 42.4105.4]). However, only 38.3% of adult
IgAN patients saw an improvement in eGFR from
biopsy to enrollment, compared to 55.9% of IgAV
patients (P ¼ 0.05). This resulted in signiﬁcant dif-
ferences in eGFR at the time of enrollment: 53.3 ml/
min per 1.73 m2 (IQR ¼ 36.584.4) for adult IgAN
patients versus 80.1 ml/min per 1.73 m2 (IQR ¼
49.2100.2) for adult IgAV patients (P ¼ 0.001). At
the time of biopsy, 71.1% of adult IgAN and 66.7%
of adult IgAV patients with an available UPCR mea-
sure had UPCR >1 g/g. Although 59.2% of adult
patients saw an improvement in proteinuria from
biopsy to enrollment, only 23.1% and 28.2% of IgAN
and IgAV patients, respectively, had a UPCR <0.3 g/
g at enrollment.
Comparison of Pediatric to Adult Patients by
Disease
Demographics (except age) did not differ signiﬁcantly
between adults and children with IgAN (Table 2).
However, signiﬁcant differences in laboratory values
were observed. Similarly, when compared to adult
patients, children with IgAN had signiﬁcantly higher
median eGFR at the time of biopsy (98.6 ml/min per
1.73 m2 [IQR ¼ 75.9122.0] vs. 51.8 ml/min per 1.73 m2
[IQR ¼ 36.087.2], P < 0.001) and at the time of
enrollment (96.5 ml/min per 1.73 m2 [IQR¼ 83.9117.6]
vs. 53.3 ml/min per 1.73 m2 [IQR ¼ 36.584.4],
P< 0.001). In contrast, there was little difference in the
percentage of pediatric and adult patients with an
improvement in eGFR.
For IgAV, proteinuria, hematuria, and serum albu-
min were similar between pediatric and adult IgAV
patients at biopsy and enrollment. Pediatric patients
had signiﬁcantly higher median eGFR at the time of
biopsy (109.5 ml/min per 1.73 m2 [IQR ¼ 82.4127.7]
vs. 67.3 ml/min per 1.73 m2 [IQR ¼ 42.4105.4], P <1377
Table 2. Patient characteristics in the CureGN IgA nephropathy (IgAN)/IgA vasculitis (IgAV) cohort, by diagnosis and age
IgAN IgAV P valuea
Pediatric n [ 173 Adult n [ 333 Pediatric n [ 112 Adult n [ 49
IgAN Ped.
versus Adult
IgAV Ped.
versus Adult
Ped. IgAN
versus IgAV
Adult IgAN
versus IgAV
Median (IQR) or
n (%)
Median (IQR) or
n (%)
Median (IQR) or
n (%)
Median (IQR) or
n (%)
Demographicsb
Age at diagnosis, yr 12.1 (9.0–14.9) 38.3 (29.1–50.0) 9.1 (6.8–13.3) 34.6 (24.0–48.5) <0.001 <0.001 <0.001 0.13
Age at biopsy, yr 12.5 (9.9–15.2) 39.6 (30.1–50.7) 9.5 (6.9–13.6) 35.4 (25.8–48.5) <0.001 <0.001 <0.001 0.13
Time from diagnosis to enrollment, yr 1.3 (0.4–3.0) 1.1 (0.3–3.3) 0.6 (0.2–1.5) 0.8 (0.2–1.9) 0.66 0.57 <0.001 0.10
Sex, male 107 (61.8%) 196 (58.9%) 71 (63.4%) 29 (59.2%) 0.51 0.61 0.79 0.97
Race, white 136 (82.4%) 238 (77.0%) 99 (91.7%) 40 (85.1%) 0.17 0.22 0.03 0.21
Hispanic/Latino 21 (12.2%) 60 (18.1%) 12 (10.7%) 7 (14.3%) 0.09 0.52 0.70 0.51
Family history of kidney disease 51 (30.5%) 98 (30.5%) 25 (23.6%) 14 (29.2%) 1.00 0.46 0.21 0.85
At biopsyc
UPCR 1.1 (0.3–2.3) 1.6 (0.9–3.3) 2.1 (0.7–5.0) 1.5 (0.7–3.7) <0.001 0.36 <0.001 0.76
3 # UPCR 22 (18.0%) 67 (28.5%) 41 (40.6%) 11 (30.6%) <0.001 0.18 0.001 0.68
1 # UPCR < 3 40 (32.8%) 100 (42.6%) 24 (23.8%) 13 (36.1%)
0.3 # UPCR < 1 32 (26.2%) 54 (23.0%) 24 (23.8%) 11 (30.6%)
UPCR <0.3 28 (23.0%) 14 (6.0%) 12 (11.9%) 1 (2.8%)
Hematuria
Negative 4 (3.1%) 20 (9.0%) 3 (2.9%) 0 (0.0%) <0.001 0.84 0.49 0.01
Trace 4 (3.1%) 11 (5.0%) 2 (2.0%) 0 (0.0%)
1þ Small, 11–25 6 (4.6%) 27 (12.2%) 7 (6.9%) 1 (2.8%)
2þ Moderate, 26–50 16 (12.3%) 62 (28.1%) 20 (19.6%) 7 (19.4%)
3þ Large, 51–250 100 (76.9%) 101 (45.7%) 70 (68.6%) 28 (77.8%)
Serum albumin, g/dl 3.7 (3.2–4.1) 3.8 (3.4–4.2) 3.4 (2.9–3.8) 3.5 (2.9–3.8) 0.07 0.63 0.001 0.002
Serum albumin <3 g/dl 23 (18.9%) 30 (12.3%) 28 (27.7%) 10 (28.6%) 0.10 0.92 0.12 0.01
eGFR, ml/min per 1.73 m2 98.6 (75.9–122.0) 51.8 (36.0–87.2) 109.5 (82.4–127.7) 67.3 (42.4–105.4) <0.001 <0.001 0.07 0.11
90 # eGFR 83 (59.7%) 67 (23.5%) 73 (67.0%) 16 (39.0%) <0.001 <0.001 0.24 0.13
60 # eGFR < 90 40 (28.8%) 57 (20.0%) 28 (25.7%) 6 (14.6%)
30 # eGFR < 60 13 (9.4%) 114 (40.0%) 4 (3.7%) 11 (26.8%)
eGFR <30 3 (2.2%) 47 (16.5%) 4 (3.7%) 8 (19.5%)
At enrollmentd
UPCR 0.3 (0.1–1.0) 1.0 (0.3–2.2) 0.5 (0.2–1.3) 0.8 (0.2–2.4) <0.001 0.22 0.07 0.54
3 # UPCR 14 (9.8%) 44 (16.9%) 17 (16.5%) 6 (15.4%) <0.001 0.24 0.13 0.91
1 # UPCR < 3 22 (15.4%) 88 (33.8%) 16 (15.5%) 12 (30.8%)
0.3 # UPCR < 1 36 (25.2%) 68 (26.2%) 33 (32.0%) 10 (25.6%)
UPCR <0.3 71 (49.7%) 60 (23.1%) 37 (35.9%) 11 (28.2%)
Hematuria
Negative 24 (17.4%) 44 (17.7%) 15 (15.3%) 1 (2.7%) 0.06 0.11 0.55 0.02
Trace 10 (7.2%) 27 (10.8%) 7 (7.1%) 4 (10.8%)
1þ Small, 11–25 17 (12.3%) 43 (17.3%) 6 (6.1%) 6 (16.2%)
2þ Moderate, 26–50 29 (21.0%) 66 (26.5%) 24 (24.5%) 7 (18.9%)
3þ Large, 51–250 58 (42.0%) 69 (27.7%) 46 (46.9%) 19 (51.4%)
Serum albumin, g/dl 4.0 (3.7–4.3) 4.0 (3.6–4.3) 3.9 (3.4–4.2) 3.9 (3.4–4.3) 0.78 0.56 0.05 0.51
Serum albumin <3 g/dl 11 (9.2%) 16 (6.4%) 15 (16.1%) 6 (20.0%) 0.33 0.62 0.12 0.01
eGFR, ml/min per 1.73 m2 96.5 (83.9–117.6) 53.3 (36.5–84.4) 104.6 (89.7–121.5) 80.1 (49.2–100.2) <0.001 <0.001 0.05 0.001
90 # eGFR 98 (64.5%) 69 (22.3%) 77 (74.0%) 17 (41.5%) <0.001 <0.001 0.42 0.02
60 # eGFR < 90 48 (31.6%) 68 (21.9%) 23 (22.1%) 11 (26.8%)
30 # eGFR < 60 3 (2.0%) 119 (38.4%) 2 (1.9%) 9 (22.0%)
eGFR <30 3 (2.0%) 54 (17.4%) 2 (1.9%) 4 (9.8%)
Hypertensione 20 (12.1%) 69 (21.9%) 24 (22.2%) 8 (17.0%) 0.01 0.46 0.03 0.45
Trajectoryf
eGFR higher at enrollment than at
biopsy
55 (42.3%) 101 (38.3%) 40 (39.6%) 19 (55.9%) 0.44 0.10 0.68 0.05
UPCR lower at enrollment than at
biopsy
72 (64.9%) 114 (60.3%) 66 (68.8%) 15 (51.7%) 0.43 0.09 0.55 0.38
UPCR ever <0.3 prior to or at
enrollment
94 (59.1%) 90 (28.7%) 46 (42.2%) 17 (37.0%) <0.001 0.54 0.01 0.25
eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; UPCR, urine protein-to-creatinine ratio.
aP value from MannWhitney U test for continuous variables, c2 test, or Fisher exact test for categorical variables.
bLess than 6% missing for demographic variables.
cTotal of 26% of UPCR, 27% of hematuria, 25% of serum albumin, and 14% of eGFR values unavailable at biopsy.
dTotal of 18% of UPCR, 22% of hematuria, 26% of serum albumin, 9% of eGFR, and 5% of hypertension values missing at enrollment.
eSystolic blood pressure >140 or diastolic blood pressure >90 for adults; systolic or diastolic blood pressure >95th percentile for pediatric patients.
fTotal of 21% of eGFR trajectories and 36% of UPCR trajectories unavailable (trajectories require nonmissing values at biopsy and enrollment), and 6% of patients had no UPCR
measurements recorded prior to or at enrollment.
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1.73 m2 [IQR ¼ 89.7121.5] vs. 80.1 ml/min per 1.73
m2 [IQR ¼ 49.2100.2], P < 0.001). From biopsy to
enrollment, the percentage of pediatric IgAV patients
with improved eGFR was not statistically signiﬁcantly
different compared to that for adults, or for improve-
ment in UPCR.
To begin to investigate the role of disease type and
age on the degree of proteinuria and eGFR, preliminary
analyses were performed evaluating the impact of each
variable on these outcomes. In a multivariable model,
age group (pediatric vs. adult, P < 0.001) and disease
classiﬁcation (IgAN vs. IgAV, P <0 .001) predicted
eGFR at enrollment. Results were similar for eGFR at
biopsy. In a similar model evaluating the degree of
proteinuria at enrollment, only age group was signiﬁ-
cant (P < 0.001) and disease type was not. At biopsy,
age group and disease type were both signiﬁcant (P ¼
0.002 and P ¼ 0.01, respectively). Although the impact
of age was expected, the results also suggest an impact
of disease type after accounting for age. It will be
important to follow these patients longitudinally to
better understand the impact of age and to assess
whether there are fundamental disease differences as
well.Treatment
Table 3 presents a description of the immunosuppres-
sion treatment at or prior to enrollment, comparing
patients with IgAN and IgAV. Individuals with IgAV
were more likely to receive immunosuppressive ther-
apy (79.5% vs. 54.0%, P < 0.001). Of the patients with
IgAV, 35% had been treated with $2 immunosup-
pressive medications at the time of enrollment,
compared to 20.5% of those with IgAN. Individuals
with IgAV were signiﬁcantly more likely to receive
cyclophosphamide and corticosteroids at or prior to
enrollment. The difference in number ofTable 3. Immunosuppression use, by diagnosisa
IgAN n [ 506 IgAV n [ 161
P valuen (%) n (%)
Number of medication classes usedb
0 232 (46.0%) 33 (20.5%) <0.001
1 169 (33.5%) 71 (44.1%)
2 77 (15.3%) 49 (30.4%)
3 23 (4.6%) 5 (3.1%)
4 3 (0.6%) 3 (1.9%)
Medication class
Cyclophosphamide 22 (4.3%) 17 (10.6%) 0.004
Azathioprine 22 (4.3%) 13 (8.1%) 0.07
Mycophenolate mofetil 61 (12.1%) 28 (17.4%) 0.09
Corticosteroids 257 (50.8%) 124 (77.0%) <0.001
RAAS blockade 411 (81.2%) 113 (70.2%) 0.002
aImmunosuppression use at or before enrollment visit.
bMissing medication data for 2 patients.
Kidney International Reports (2018) 3, 1373–1384immunosuppressive drug exposures persisted when
the pediatric and adult cohorts were analyzed sepa-
rately (Table 4). Among pediatric patients, those with
IgAV were more likely to receive corticosteroids
compared to those with IgAN (73.2% vs. 46.2%, P <
0.001). In the adult cohort, those with IgAV were more
likely to receive cyclophosphamide and corticosteroids
compared with IgAN (16.3% vs. 4.5%, P ¼ 0.001 and
85.7% vs. 53.2%, P < 0.001, respectively). Although
there was not a statistically signiﬁcant difference in use
of reninangiotensinaldosterone system (RAAS)
blockade between diseases, adult patients were more
likely to receive RAAS blockade irrespective of diag-
nosis (88.5% vs. 65.7%, P < 0.001).DISCUSSION
The CureGN study represents a large, collaborative,
multicenter effort to address major knowledge gaps in
the ﬁeld of primary glomerular diseases. We present
data on the IgA cohort, the ﬁrst of the 4 CureGN co-
horts to reach the enrollment target. This cohort rep-
resents, to the best of our knowledge, the largest
prospective cohort of patients with IgA kidney disease
with full clinical data, biospecimens, and centralized
digital pathology. A unique feature of this cohort is the
wide range of patients enrolled, including both IgAN
and IgAV, as well as children and adults. A breadth of
chronic kidney disease stages are well represented in
CureGN, and many participants are at moderate to high
risk of progression, based on proteinuria and eGFR at
biopsy and/or enrollment. Taking advantage of the
diversity of this cohort, we are able to demonstrate
important differences in clinical features of IgAV and
IgAN between children and adults. Furthermore, we
describe differences in the treatment patterns between
IgAN and IgAV, showing that those with IgAV are
more likely to be treated aggressively with immuno-
suppressive medications but are less likely to receive
standard supportive care with RAAS inhibition.
Current clinical practice guidelines and observational
studies suggest that patients with IgAN with UPCR >1
g/g have a moderate to high risk of progressive kidney
function loss.10,18 Using this cutpoint, we demonstrate
that there are signiﬁcant differences in the evolution of
proteinuria in children and adults within this cohort.
Based on reported proteinuria at the time of biopsy,
64.3% of the CureGN IgA cohort with an available
UPCR measure had a UPCR >1 g/g, including 50.8% of
pediatric IgAN, 71.1% of adult IgAN, 64.4% of pedi-
atric IgAV, and 66.7% of adult IgAV patients. There
was substantial reduction in proteinuria in both pedi-
atric IgA disease groups between biopsy and enroll-
ment, resulting in normalization of the UPCR to<0.3 g/g1379
Table 4. Immunosuppression use, by diagnosis and agea
Pediatric
P value
Adult
P value
IgAN n [ 173 IgAV n [ 112 IgAN n [ 333 IgAV n [ 49
n (%) n (%) n (%) n (%)
Number of medications usedb
0 85 (49.7%) 27 (24.1%) <0.001 147 (44.1%) 6 (12.2%) <0.001
1 44 (25.7%) 44 (39.3%) 125 (37.5%) 27 (55.1%)
2 34 (19.9%) 37 (33.0%) 43 (12.9%) 12 (24.5%)
3 8 (4.7%) 2 (1.8%) 15 (4.5%) 3 (6.1%)
4 0 (0.0%) 0 (0.0%) 3 (0.9%) 1 (2.0%)
Medication class
Cyclophosphamide 7 (4.0%) 9 (8.0%) 0.16 15 (4.5%) 8 (16.3%) 0.001
Azathioprine 9 (5.2%) 10 (8.9%) 0.23 13 (3.9%) 3 (6.1%) 0.47
Mycophenolate mofetil 25 (14.5%) 23 (20.5%) 0.19 36 (10.8%) 5 (10.2%) 0.90
Corticosteroids 80 (46.2%) 82 (73.2%) <0.001 177 (53.2%) 42 (85.7%) <0.001
RAAS blockade 116 (67.1%) 70 (62.5%) 0.36 295 (88.6%) 43 (87.8%) 0.86
aImmunosuppression use at or before enrollment visit.
bMissing medication data for 2 patients.
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ment with IgAN and IgAV, respectively. In contrast,
although more than half of the adult patients saw an
improvement in proteinuria between biopsy and
enrollment, only 23.1% and 28.2% of IgAN and IgAV
adult patients, respectively, had a UPCR <0.3 g/g at
enrollment.
Age-based differences were also observed in eGFR
at the time of biopsy. Speciﬁcally, the eGFR was quite
low in adults with IgAN with a median of 51.8 ml/min
per 1.73 m2 and IgAV of 67.3 ml/min per 1.73 m2
compared with children (98.6 ml/min per 1.73 m2 and
109.5 ml/min per 1.73 m2, respectively). Between bi-
opsy and enrollment, approximately 40% of all IgAN
patients and pediatric IgAV patients had an
improvement in eGFR, whereas 55.9% of adult IgAV
patients showed an improvement. Longer observation
will help to improve our understanding of differential
eGFR trajectories in these patients. The long-term
observation planned for the CureGN study, the
anticipated entry of digitized pathology of the kidney
biopsies into the CureGN database, and the avail-
ability of serial biological samples to test for bio-
markers will be key components in the effort to better
predict renal prognosis and to identify which patients
with IgA disease may beneﬁt the most from available
therapies.
Antiproteinuric therapy using angiotensin-
converting enzyme inhibitors or angiotensin receptor
blockers is a hallmark of treating IgAN. Not surpris-
ingly, use of RAAS blockers was common in CureGN
participants with IgAN and IgAV, with approximately
90% of adult and 65% of pediatric participants using
these therapies at some point in their disease course at
or prior to enrollment. However, pediatric IgAV
patients were more likely to receive immunosuppres-
sant medications than RAAS blockade. Outside of the1380crescentic forms of IgAN and IgAV, the use of
immunosuppression in these diseases remains contro-
versial. A number of small randomized studies have
shown efﬁcacy in adding a course of corticosteroids to
RAAS blockade for patients with IgAN.19–21 The 2012
KDIGO Clinical Practice Guideline for Glomerulone-
phritis suggests that IgAN patients with persistent
proteinuria >1 g/d, despite optimal supportive care,
receive a 6-month course of corticosteroids. However,
the more recent STOP-IgAN (Supportive Versus
Immunosuppressive Therapy for the Treatment of
Progressive IgA Nephropathy) trial10 and TESTING
(The Therapeutic Evaluation of Steroids in IgA Ne-
phropathy Global) study12 have questioned the beneﬁt
of such a treatment strategy. In the CureGN cohort,
half of the IgAN patients received immunosuppression
with corticosteroids (257 of 506, 50.8%), clearly the
most commonly used agent. Approximately 75% of
the IgAV patients were treated with a course of cor-
ticosteroids, although it is unclear whether therapy
was targeted primarily at kidney involvement, as
these percentages do not correlate with the prevalence
of proteinuria >1 g/d at enrollment. Also of interest,
many pediatric and adult patients with IgAN or IgAV
received other immunosuppressive agents—including
cyclophosphamide, azathioprine, and mycophenolate
mofetil—for which the evidence base is even less
conclusive than that for corticosteroids. Recently,
there has been a call to tailor treatment with cortico-
steroids (and other immunomodulatory agents) in
IgAN and IgAV to those patients who will receive the
most beneﬁt and the least harm.22 The CureGN cohort
will couple the clinical data presented here with
detailed histopathology, biomarker, genetic, and lon-
gitudinal follow-up data on all its participants. This
cohort, therefore, is well positioned to begin to inform
these important questions.Kidney International Reports (2018) 3, 1373–1384
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there are several limitations that should be acknowl-
edged. The main limitation is that the centralized
digital pathology repository is currently under
development, via which standardized biopsy scoring
will be performed for this cohort. These data will
surely complement the clinical data presented in this
analysis, but will not be complete for several years.
Nevertheless, the patients included in our cohort
meet strict biopsy diagnostic criteria based on local
pathology evaluations. Another limitation is that for
prevalent patients, some of the clinical data were
collected retrospectively and as such are subject to
inherent issues such as unavailability, and a lack of
granularity, which can occur in circumstances such as
transfer of care following diagnosis. To this end, some
particular limitations include data about the timing
and duration of RAAS blockade prior to enrollment
and the degree of missing data (including 25% with
unavailable urine data at biopsy). Finally, the time for
analysis in the cohort is still relatively short,
encompassing the time from biopsy diagnosis to
study enrollment. This precludes detailed analysis of
kidney disease outcomes and limits our analyses to
assessment of baseline data at the time of biopsy and
enrollment. Furthermore, the time from biopsy to
enrollment differed signiﬁcantly between diseases, so
caution should be paid when interpreting changes in
eGFR and proteinuria between disease cohorts.
Despite these limitations, our results already provide
several novel insights about clinical features of these
disorders, and highlight important differences in the
existing treatment strategies.
In summary, the CureGN cohort represents the
largest multicenter, prospectively followed cohort of
IgAN and IgAV patients. The prospective design of the
CureGN study, along with its stringent biopsy-based
enrollment criteria, make this cohort less susceptible
to the confounding factors inherent to prior
retrospective and cross-sectional analyses.23–36 Impor-
tant features of the cohort include the following:
(i) enrollment of participants within 5 years of
kidney biopsy; (ii) inclusion of both IgAN and IgAV;
(iii) inclusion of all chronic kidney disease stages
except dialysis and transplantation; (iv) inclusion of
pediatric and adult patients; (v) rigorous and stan-
dardized prospective data collection across multiple
sites; (vi) comprehensive longitudinal biobank for all
recruited participants; and (vii) the emerging stan-
dardized central digital pathology repository. Our
baseline description of this unique cohort lays the
foundation for future clinical and translational studies
of IgA-related glomerulonephritis within the CureGN
study. The long-term observation planned for theKidney International Reports (2018) 3, 1373–1384CureGN study, the anticipated availability of digital
kidney biopsy pathology, and the collection of serial
biological samples to permit biomarker analysis will be
key components in better predicting renal prognosis
and identifying patients most appropriate for speciﬁc
therapies.DISCLOSURE
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